Author: He, Yang; Cao, Lingling; Wang, Li; Liu, Lingping; Huang, Ying; Gong, Xuan
Title: Metformin Inhibits Proliferation of Human Thyroid Cancer TPC-1 Cells by Decreasing LRP2 to Suppress the JNK Pathway Document date: 2020_1_6
ID: uzatktbf_1
Snippet: Thyroid cancer is the most common malignancy in endocrine-related tumors. In recent years, thyroid cancer has been well concerned because of the rapid rise in its incidence. 1 As a first-line drug applied for T2DM (type 2 diabetes mellitus), metformin contributes to stabilize blood glucose levels through inhibiting gluconeogenesis and reducing hepatic glycogenolysis. 2 Interestingly, the application of metformin sharply decreases the incidences o.....
Document: Thyroid cancer is the most common malignancy in endocrine-related tumors. In recent years, thyroid cancer has been well concerned because of the rapid rise in its incidence. 1 As a first-line drug applied for T2DM (type 2 diabetes mellitus), metformin contributes to stabilize blood glucose levels through inhibiting gluconeogenesis and reducing hepatic glycogenolysis. 2 Interestingly, the application of metformin sharply decreases the incidences of tumor diseases, suppresses the growth of malignant cells and enhances chemotherapy-sensitivity. 3 Therefore, metformin may exert a potential anti-tumor role. It is expected to be an adjuvant drug for the treatment of thyroid cancer.
Search related documents:
Co phrase search for related documents- line drug and malignant cell: 1
Co phrase search for related documents, hyperlinks ordered by date